Natera (NTRA) to Release Earnings on Thursday

Natera (NASDAQ:NTRA) will likely be issuing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Natera to post earnings of ($0.46) per share and revenue of $600.6780 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Natera Trading Up 2.0%

NTRA stock opened at $215.53 on Thursday. The firm has a market cap of $29.81 billion, a PE ratio of -94.12 and a beta of 1.64. Natera has a 1 year low of $125.38 and a 1 year high of $256.36. The company has a fifty day simple moving average of $228.87 and a 200 day simple moving average of $200.64.

Insider Buying and Selling at Natera

In other Natera news, Director Herm Rosenman sold 48,419 shares of the firm’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $227.42, for a total value of $11,011,448.98. Following the completion of the sale, the director owned 20,342 shares in the company, valued at approximately $4,626,177.64. This trade represents a 70.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Burkes Brophy sold 37,175 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $242.54, for a total transaction of $9,016,424.50. Following the completion of the sale, the chief financial officer directly owned 64,123 shares of the company’s stock, valued at approximately $15,552,392.42. This represents a 36.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 443,119 shares of company stock worth $103,665,782 over the last quarter. Corporate insiders own 5.63% of the company’s stock.

Hedge Funds Weigh In On Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Mercer Global Advisors Inc. ADV raised its holdings in shares of Natera by 2.9% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 62,807 shares of the medical research company’s stock worth $14,389,000 after acquiring an additional 1,799 shares during the period. First Citizens Bank & Trust Co. increased its holdings in Natera by 4.1% during the 4th quarter. First Citizens Bank & Trust Co. now owns 2,102 shares of the medical research company’s stock worth $482,000 after purchasing an additional 82 shares in the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Natera in the 4th quarter valued at about $535,000. Mackenzie Financial Corp lifted its holdings in shares of Natera by 1.5% in the fourth quarter. Mackenzie Financial Corp now owns 10,615 shares of the medical research company’s stock valued at $2,436,000 after purchasing an additional 152 shares in the last quarter. Finally, Regal Partners Ltd acquired a new position in shares of Natera during the fourth quarter worth about $1,718,000. 99.90% of the stock is owned by institutional investors.

Analyst Ratings Changes

NTRA has been the subject of a number of research reports. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Piper Sandler increased their target price on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. BNP Paribas Exane raised Natera to a “hold” rating and set a $172.00 target price on the stock in a research report on Monday, October 27th. Wells Fargo & Company upped their price target on Natera from $190.00 to $205.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Finally, Barclays raised their price objective on Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $249.20.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.